Flunarizine
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Flunarizine
Flunarizine: Known uses and market status in Canada
Summary
The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Flunarizine, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The one known use is migraine disorder, which is supported by an official label.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 1 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| migraine disorder | official label (curated); approved indication: migraine |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 02246082 | FLUNARIZINE | Valid |
Safety Considerations
- Known adverse effects (general pharmacological knowledge, not from the Canadian label): sedation, weight gain, depression, and extrapyramidal symptoms or parkinsonism. Extra caution is warranted in elderly patients and in those with a history of depression.
- Drug Interactions: The data list 4 pharmacology interaction entries, all describing targets rather than interacting drugs: D2 receptor, Cav3.1, Cav3.2 and Cav3.3. A Phase 1 study (NCT00752466) examined the pharmacokinetic interaction of flunarizine with topiramate.
Please refer to the package insert for the full warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.